Prostate-derived ets factor represses tumorigenesis and modulates epithelial-to-mesenchymal transition in bladder carcinoma cells

Cancer Letters

Volumn 375, Issue 1, 2016, Pages 142-151

  Tsui, Ke Hung ^a,b   Lin, Yu Hsiang ^a,b   Chung, Li Chuan ^b   Chuang, Sung Ting ^b   Feng, Tsui Hsia ^b   Chiang, Kun Chun ^a   Chang, Phei Lang ^a,b   Yeh, Chi Ju ^b   Juang, Horng Heng ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Bladder; Invasion; MASPIN; NDRG family genes; PDEF; Tumorigenesis

Indexed keywords

F ACTIN; MASPIN; PROSTATE DERIVED ETS FACTOR; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; SPDEF PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL TRANSLOCATION GENE 2; BLADDER CANCER CELL LINE; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; CANCER GRADING; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; KAI1 GENE; MALE; MASPIN GENE; MOUSE; N MYC DOWNSTREAM REGULATED GENE 1; NONHUMAN; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; ANIMAL; BAGG ALBINO MOUSE; BLADDER TUMOR; CANCER TRANSPLANTATION; CARCINOGENESIS; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION; TUMOR VOLUME;

ANIMALS; CARCINOGENESIS; CELL LINE, TUMOR; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PROTO-ONCOGENE PROTEINS C-ETS; TUMOR BURDEN; URINARY BLADDER NEOPLASMS;

EID: 84960452408     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.02.056     Document Type: Article

References (50)

1. Chavan S., Bray F., Lortet-Tieulent J., Goodman M., Jemal A. International variations in bladder cancer incidence and mortality. Eur. Urol 2014, 66:59-73.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J. Clin 2013, 63:11-30.
3. Goodison S., Rosser C.J., Urquidi V. Bladder cancer detection and monitoring: assessment of urine- and blood based marker tests. Mol. Diagn. Ther 2013, 17:71-84.
4. Gutierrez-Hartmann A., Duval D.L., Bradford A.P. ETS transcription factors in endocrine systems. Trends Endocrinol. Metab 2007, 18:150-158.
5. Seth A., Waston D.K. ETS transcription factors and their emerging roles in human cancer. Eur. J. Cancer 2005, 41:2462-2478.
6. Oettgen P., Finger E., Sun Z., Akbarali Y., Thamrongsak U., Boltax J., et al. PDEF, a novel prostate epithelium-specific ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression. J. Biol. Chem 2000, 275:1216-1225.
7. Yamada N., Tamai Y., Miyamoto H., Nozaki M. Cloning and expression of the mouse Pse gene encoding a novel Ets family member. Gene 2000, 241:267-274.
8. Sood A.K., Kim H., Geradts J. PDEF in prostate cancer. Prostate 2012, 72:592-596.
9. Nozawa M., Yomogida K., Kanno N., Nonomura N., Miki T., Okuyama A., et al. Prostate-specific transcription factor hPSE is translated only in normal prostate epithelial cells. Cancer Res 2000, 60:1348-1352.
10. Feldman R.J., Sementchenko V.I., Gayed M., Fraig M.M., Watson D.K. Pdef expression in human breast cancer is correlated with invasive potential and altered gene expression. Cancer Res 2003, 63:4626-4631.
11. Tsui K.H., Chung L.C., Feng T.H., Chang P.L., Juang H.H. Upregulation of prostate-derived ets factor by luteolin causes inhibition of cell proliferation and cell invasion in prostate carcinoma cells. Int. J. Cancer 2012, 130:2812-2823.
12. Steffan J.J., Koul H.K. Prostate derived ETS fact (PDEF): a putative tumor metastasis suppressor. Cancer Lett 2011, 310:109-117.
13. Bryan R.T., Tselepis C. Cadherin switching and bladder cancer. J. Urol 2010, 184:423-431.
14. Muramaki M., Miyake H., Terakawa T., Kumano M., Sakai I., Fujisawa M. Expression profile of E-cadherin and N-cadherin in non-muscle-invasive bladder cancer as a novel predictor of intravesical recurrence following transurethral resection. Urol. Oncol 2012, 30:161-166.
15. Wu K., Zeng J., Zhou J., Fan J., Chen Y., Wang Z., et al. Slug contributes to cadherin switch and malignant progression in muscle-invasive bladder cancer development. Urol. Oncol 2013, 31:1751-1760.
16. Li G., Liu Y., Yin H., Zhang X., Mo X., Tang J., et al. E-cadherin gene promoter hypermethylation may contribute to the risk of bladder cancer among Asian populations. Gene 2014, 534:48-53.
17. Turner D.P., Moussa O., Sauane M., Fisher P.B., Watson D.K. Prostate-derived ETS factor is a mediator of metastatic potential through the inhibition of migration and invasion in breast cancer. Cancer Res 2007, 67:1618-1625.
18. Findlay V.J., Turner D.P., Yordy J.S., McCarragher B., Shriver M.R., Szalai G., et al. Prostate-derived ets factor regulates epithelial-to-mesenchymal transition through both slug-dependent and independent mechanisms. Genes Cancer 2011, 2:120-129.
19. Scheiber M.N., Watson P.M., Rumboldt T., Stanley C., Wilson R.C., Findlay V.J., et al. FLI1 expression is correlated with breast cancer cellular growth, migration, and invasion and altered gene expression. Neoplasia 2014, 16:801-813.
20. Gu X., Zerbini L.F., Otu H.H., Bhasin M., Yang Q., Joseph M.G., et al. Reduced PDEF expression increases invasion and expression of mesenchymal gene in prostate cancer cells. Cancer Res 2007, 67:4219-4226.
21. Rigby C.C., Franks L. A human tissue culture cell line from a transitional cell tumor of the urinary bladder: growth, chromosome pattern and ultrastructure. Br. J. Cancer 1970, 24:746-754.
22. Rasheed S., Gardner M.B., Rongey R.W., Nelson-Rees W.A., Arnstein P. Human bladder carcinoma: characterization of two new tumor cell lines and search for tumor viruses. J. Natl Cancer Inst 1977, 58:881-890.
23. Bubeník J., Baresová M., Viklický V., Jakoubková J., Sainerová H., Donner J. Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen. Int. J. Cancer 1973, 11:765-773.
24. Juang H.H., Lin Y.F., Chang P.L., Tsui K.H. Cardiac glycosides decrease prostate specific antigen expression by down-regulation of prostate derived ets factor. J. Urol 2010, 184:2158-2164.
25. Tsui K.H., Hsu S.Y., Chung L.C., Lin Y.H., Feng T.H., Lee T.Y., et al. Growth differentiation factor-15: a p53- and demethylation-upregulating gene represses cell proliferation, invasion, and tumorigenesis in bladder carcinoma cells. Sci. Rep 2015, 5:12870.
26. Lee J.C., Chung L.C., Chen Y.J., Feng T.H., Chen W.T., Juang H.H. Upregulation of B-cell translocation gene 2 by epigallocatechin-3-gallate via p38 and ERK signaling blocks cell proliferation in human oral squamous carcinoma cells. Cancer Lett 2015, 360:310-318.
27. Chiang K.C., Tsui K.H., Chung L.C., Yeh C.N., Chang P.L., Chen W.T., et al. Topoisomerase inhibitors modulate gene expression of B-cell translocation gene 2 and prostate specific antigen in prostate carcinoma cells. PLoS ONE 2014, 9:e89117.
28. Lee J.C., Chung L.C., Chen Y.J., Feng T.H., Juang H.H. N-myc downstream-regulated gene 1 downregulates cell proliferation, invasiveness and tumorigenesis in human oral squamous cell carcinoma. Cancer Lett 2014, 355:242-252.
29. Tsui K.H., Wang S.W., Chung L.C., Feng T.H., Lee T.Y., Chang P.L., et al. Mechanisms by which interleukin-6 attenuates cell invasion and tumorigenesis in human bladder carcinoma cells. Biomed Res. Int 2013, 2013:791212.
30. Noah T.K., Lo Y.H., Price A., Chen G., King E., Washington M.K., et al. SPDEF functions as a colorectal tumor suppressor by inhibiting β-catenin activity. Gastroenterology 2013, 144:1012-1023.
31. Cheng X.H., Black M., Ustiyan V., Le T., Fulford L., Sridharan A., et al. SPDEF inhibits prostate carcinogenesis by disrupting a positive feedback loop in regulation of the Foxm1 oncogene. PLoS Genet 2014, 10:e1004656.
32. Buchwalter G., Hickey M.M., Cromer A., Selfors L.M., Gunawardane R.N., Frishman J., et al. PDEF promotes luminal differentiation and acts as a survival factor for ER-positive breast cancer cells. Cancer Cell 2013, 23:753-767.
33. Ghadersohi A., Odunsi K., Lele S., Collins Y., Greco W.R., Winston J., et al. Prostate derived Ets transcription factor shows better tumor-association than other cancer-associated molecules. Oncol. Rep 2004, 11:453-458.
34. Rodabaugh K.J., Mhawech-Fauceglia P., Groth J., Lele S., Sood A.K. Prostate-derived Ets factor is overexpressed in serous epithelial ovarian tumors. Int. J. Gynecol. Pathol 2007, 26:10-15.
35. Ghadersohi A., Pan D., Fayazi Z., Hicks D.G., Winston J.S., Li F. Prostate-derived Ets transcription factor (PDEF) downregulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor formation in vivo. Breast Cancer Res. Treat 2007, 102:19-30.
36. Schaefer J.S., Sabherwal Y., Shi H.Y., Sriraman V., Richards J., Minella A., et al. Transcriptional regulation of p21/CIP1 cell cycle inhibitor by PDEF controls cell proliferation and mammary tumor progression. J. Biol. Chem 2010, 285:11258-11269.
37. Beecken W.D., Engl T., Engels K., Blumenberg C., Oppermann E., Camphausen K., et al. Clinical relevance of maspin expression in bladder cancer. World J. Urol 2006, 24:338-344.
38. Fristrup N., Ulhøi B.P., Birkenkamp-Demtröder K., Mansilla F., Sanchez-Carbayo M., Segersten U., et al. Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer. Am. J. Pathol 2012, 180:1824-1834.
39. Mao B., Zhang Z., Wang G. BTG2: a rising star of tumor suppressors. Int. J. Oncol 2015, 46:459-464.
40. Hoffman K.L., Lerner S.P., Smith C.L. Raloxifene inhibits growth of RT4 urothelial carcinoma cells via estrogen receptor-dependent induction of apoptosis and inhibition of proliferation, Horm. Cancer 2013, 4:24-35.
41. Wagener N., Bulkescher J., Macher-Goeppinger S., Karapanagiotou-Schenkel I., Hatiboglu G., Abdel-Rahim M., et al. Endogenous BTG2 expression stimulates migration of bladder cancer cells and correlates with poor clinical prognosis for bladder cancer patients. Br. J. Cancer 2013, 108:973-982.
42. Melotte V., Qu X., Ongenaert M., van Criekinge W., de Bruïne A.P., Baldwin H.S., et al. The N-myc downstream regulated gene (NDRG) family: diverse functions, multiple applications. FASEB J. 2010, 24:4153-4166.
43. Sun J., Zhang D., Bae D.H., Sahni S., Jansson P., Zheng Y., et al. Metastasis suppressor, NDRG1, mediates its activity through signaling pathways and molecular motors. Carcinogenesis 2013, 34:1943-1954.
44. Tai Y.C., Weissman A.M. Dissecting the diverse functions of the metastasis suppressor CD82/KAI1. FEBS Lett 2011, 585:3166-3173.
45. Jackson P., Grimm M.O., Kingsley E.A., Brosius U., Antalis T., Yardley G., et al. Relationship between expression of KAI1 metastasis suppressor gene, mRNA levels and p53 in human bladder and prostate cancer cell lines. Urol. Oncol 2002, 7:99-104.
46. You J., Madigan M.C., Rowe A., Sajinovic M., Russell P.J., Jackson P. An inverse relationship between KAI1 expression, invasive ability, and MMP-2 expression and activity in bladder cancer cell lines. Urol. Oncol 2012, 30:502-508.
47. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
48. Lee J.M., Dedhar S., Kalluri R., Thompson E.W. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J. Cell Biol 2006, 172:973-981.
49. Akhshi T.K., Wernike D., Piekny A. Microtubules and actin crosstalk in cell migration and division. Cytoskeleton 2014, 71:1-23.
50. Liu W.M., Zhang F., Moshiach S., Zhou B., Huang C., Srinivasan K., et al. Tetraspanin CD82 inhibits protrusion and retraction in cell movement by attenuating the plasma membrane-dependent actin organization. PLoS ONE 2012, 7:e51797.